• Legend Biotech flagged preliminary Phase 1 results for LB2102 in relapsed or refractory small-cell lung cancer or large-cell neuroendocrine carcinoma, scheduled for future presentation at the 2026 ASCO annual meeting on May 31.
• The update is intended to reinforce early evidence of clinical activity in solid tumors, with a safety profile described as manageable.
• Separate new analyses from the CARTITUDE-4 study of CARVYKTI in multiple myeloma are also set for presentation on June 1, focusing on outcomes in patients who responded to bridging therapy across cytogenetic risk groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211700PRIMZONEFULLFEED9724154) on May 21, 2026, and is solely responsible for the information contained therein.